Back to News
Market Impact: 0.2
Turn Therapeutics Consensus Price Target Increased by 24.42% to $20.40
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
The aggregate one-year analyst price target for Turn Therapeutics rose 24.42% to $20.40 per share from $16.40 on September 11, 2026. The upward revision signals improved analyst valuation expectations for the biotech company, although it does not constitute an investment recommendation.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
TTRX0.45
More News
- Trump teases more inflationary money for voters ahead of midterm elections, now promising $90 payments after touting $500 and $5,000 checks
- Goldman Sachs says buy these stocks now, ahead of their earnings
- AI will create more jobs than it kills, McKinsey says. The catch: 11 million Americans may need new careers
- Gaza voters want jobs and security as Palestinian elections approach
- Spotify billionaire’s body scan startup has come to America
- I’m an obesity expert and can’t wait for the compounding craze to stop
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Run Cost-Controlled Financial Research in AllMind Agent Studio
- State of Public Markets, June 2026: Higher for Longer Meets the AI Supercycle